Intuitive Surgical Navigates 40% Drawdown as MDT and JNJ Challenge da Vinci Share
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-06. Check what remains unresolved below before relying on it.
What does this change in the investment case for Intuitive Surgical?
Competitive market entry by MDT and JNJ compresses ISRG new-system unit margins while installed-base recurring service contracts defend baseline cash flow.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factIntuitive Surgical shares have declined 40% from recent peak levels amid slowing da Vinci robot system sales growth. |
| What else was confirmed? | Reported factMedtronic and Johnson & Johnson are introducing competitive surgical robotic systems into hospital procurement channels. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for ISRG; the latest is dated 2026-09-06. |
| What would change the assessment? | UnknownSurgical Robotics Unit Placements — Quarterly da Vinci system shipments versus MDT robotic install announcements |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Intuitive Surgical shares have declined 40% from recent peak levels amid slowing da Vinci robot system sales growth.
- · Medtronic and Johnson & Johnson are introducing competitive surgical robotic systems into hospital procurement channels.
- · Recurring revenue from instruments, parts, and service agreements accounts for 75% of Intuitive Surgical's total revenue base.
Public research record
Research framework · page evidenceCompleted event assessment
valuation multiple compression offset by 75% recurring service revenue
| Type | Claim | Scope |
|---|---|---|
| Assumption | Intuitive Surgical shares have declined 40% from recent peak levels amid slowing da Vinci robot system sales growth. | 2026-09-06 |
| Interpretation | valuation multiple compression offset by 75% recurring service revenue | ISRG |
Countercase, invalidators, and sources
High procedure growth on installed da Vinci units sustains double-digit consumables expansion, stabilizing share price.
- · Surgical Robotics Unit Placements — Quarterly da Vinci system shipments versus MDT robotic install announcements
- Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning? · 2026-09-05
What remains unresolved
- Base path
- ISRG trades rangebound near valuation lows as hospital procurement budgets digest competitive options from MDT and JNJ.
- Adverse path
- Hospital systems defer da Vinci capital purchases, accelerating system pricing concessions and gross margin erosion.
- Supportive path
- High procedure growth on installed da Vinci units sustains double-digit consumables expansion, stabilizing share price.
- · Surgical Robotics Unit Placements — Quarterly da Vinci system shipments versus MDT robotic install announcementsnext month
Evidence
- Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?2026-09-05
“Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, recurring revenue from parts and services accounts for 75% of revenue.”
Supports: ISRG stock down 40% from highs as MDT and JNJ compete; recurring revenue represents 75% of sales.